Bone Metastasis - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Bone Metastasis - Pipeline Review, H1 2015’, provides an overview of the Bone Metastasis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bone Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bone Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bone Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bone Metastasis Overview 9
Therapeutics Development 10
Pipeline Products for Bone Metastasis - Overview 10
Pipeline Products for Bone Metastasis - Comparative Analysis 11
Bone Metastasis - Therapeutics under Development by Companies 12
Bone Metastasis - Therapeutics under Investigation by Universities/Institutes 14
Bone Metastasis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Bone Metastasis - Products under Development by Companies 18
Bone Metastasis - Products under Investigation by Universities/Institutes 20
Bone Metastasis - Companies Involved in Therapeutics Development 21
Ablynx NV 21
Alethia Biotherapeutics Inc. 22
Amgen Inc. 23
Amura Holdings Ltd. 24
Bayer AG 25
ChemoCentryx, Inc. 26
Debiopharm International S.A. 27
Deciphera Pharmaceuticals, LLC 28
Digna Biotech, S.L. 29
Medivir AB 30
Merrion Pharmaceuticals Plc 31
Osteologix Holdings Plc. 32
R-Pharm 33
Sigma-Tau S.p.A. 34
Bone Metastasis - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
AB-25E9 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ADM-01 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
alendronate sodium + HPMA + paclitaxel - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
alendronate sodium + paclitaxel + PEG - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ALX-0141 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AM-3701 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AMG-161 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CCX-721 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
DCC-2909 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DCC-3014 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Debio-0719 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
denosumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
disitertide - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drugs to Inhibit EGFR for Bone Metastasis - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MIV-710 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MIV-711 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NBS-101 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
P-17 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
radium Ra 223 dichloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
RPH-203 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SST-0001 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
TPH-9 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Vicrostatin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
zoledronic acid - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Bone Metastasis - Recent Pipeline Updates 79
Bone Metastasis - Dormant Projects 95
Bone Metastasis - Discontinued Products 97
Bone Metastasis - Product Development Milestones 98
Featured News & Press Releases 98
May 23, 2014: Daiichi Sankyo Receives Approval in Japan for Additional Indication Related to RANMARK for Treatment of Giant Cell Tumor of Bone 98
Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders 98
Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics 99
Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo 100
Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 101
May 30, 2013: Algeta Announces First Sale Of Xofigo In US 102
Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 103
Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride 104
Oct 23, 2012: Amgen's Xgeva Obtains Approval From NICE For Eligibility To NHS Funding 104
Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107
List Of Tables
Number of Products under Development for Bone Metastasis, H1 2015 10
Number of Products under Development for Bone Metastasis - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Bone Metastasis - Pipeline by Ablynx NV, H1 2015 21
Bone Metastasis - Pipeline by Alethia Biotherapeutics Inc., H1 2015 22
Bone Metastasis - Pipeline by Amgen Inc., H1 2015 23
Bone Metastasis - Pipeline by Amura Holdings Ltd., H1 2015 24
Bone Metastasis - Pipeline by Bayer AG, H1 2015 25
Bone Metastasis - Pipeline by ChemoCentryx, Inc., H1 2015 26
Bone Metastasis - Pipeline by Debiopharm International S.A., H1 2015 27
Bone Metastasis - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 28
Bone Metastasis - Pipeline by Digna Biotech, S.L., H1 2015 29
Bone Metastasis - Pipeline by Medivir AB, H1 2015 30
Bone Metastasis - Pipeline by Merrion Pharmaceuticals Plc, H1 2015 31
Bone Metastasis - Pipeline by Osteologix Holdings Plc., H1 2015 32
Bone Metastasis - Pipeline by R-Pharm, H1 2015 33
Bone Metastasis - Pipeline by Sigma-Tau S.p.A., H1 2015 34
Assessment by Monotherapy Products, H1 2015 35
Assessment by Combination Products, H1 2015 36
Number of Products by Stage and Target, H1 2015 38
Number of Products by Stage and Mechanism of Action, H1 2015 40
Number of Products by Stage and Route of Administration, H1 2015 42
Number of Products by Stage and Molecule Type, H1 2015 44
Bone Metastasis Therapeutics - Recent Pipeline Updates, H1 2015 79
Bone Metastasis - Dormant Projects, H1 2015 95
Bone Metastasis - Dormant Projects (Contd..1), H1 2015 96
Bone Metastasis - Discontinued Products, H1 2015 97
List Of Figures
Number of Products under Development for Bone Metastasis, H1 2015 10
Number of Products under Development for Bone Metastasis - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Products, H1 2015 17
Assessment by Monotherapy Products, H1 2015 35
Number of Products by Top 10 Targets, H1 2015 37
Number of Products by Stage and Top 10 Targets, H1 2015 37
Number of Products by Top 10 Mechanism of Actions, H1 2015 39
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 40
Number of Products by Top 10 Routes of Administration, H1 2015 41
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42
Number of Products by Top 10 Molecule Types, H1 2015 43
Number of Products by Stage and Top 10 Molecule Types, H1 2015 44
